CAMP4 receives UK trial authorization
- CAMP4 Therapeutics (NASDAQ:CAMP) received UK MHRA authorization to include United Kingdom sites in its CMP-002 Phase 1/2 trial.
- The decision follows regulatory clearances in Australia and Argentina supporting first-in-human studies.
- CAMP4 expects to begin the global Phase 1/2 trial in the fourth quarter of 2026.
CAMP4 Therapeutics (NASDAQ:CAMP) received authorization from the UK Medicines and Healthcare products Regulatory Agency to include United Kingdom sites in its planned global Phase 1/2 clinical trial of CMP-002 for SYNGAP1-related disorder.
The authorization follows July 2026 clearances from Australia’s Therapeutic Goods Administration, a Human Research Ethics Committee, and Argentina’s ANMAT for initiation of first-in-human studies.
The company expects to begin the Phase 1/2 trial in the fourth quarter of 2026, with additional regulatory submissions currently under review in the European Union.
CAMP4 Therapeutics is developing RNA-based medicines designed to restore protein expression for diseases caused by insufficient gene activity.
The company said CMP-002 will be evaluated through a global clinical program as it advances regulatory preparations across multiple regions.
Frequently asked questions
More from United States
AbbVie revenue increases 10.3% to $17.4 billion in third quarter
Sensient Q3 revenue rockets 10.6% to $455.8 million
Cameco Q3 adjusted loss reaches CA$2 million as uranium output falls
Kite Realty Q3 loss narrows to $13.3 million as NOI grows
Largo cuts 2026 vanadium production outlook to 9,500–10,500 tonnes
nVent Q3 sales jump 44% as shares fall despite higher revenue
